



TIME	SESSION	
7:30am	Breakfast Buffet (7:30 - 8:30am)	
7:45am		
8:00am		
8:15am		
Session 1 (8:30 – 10:00am)		
8:30am	Meeting Opening	Holly Janes, Member, Fred Hutch, on behalf of the organizing committee
8:45am	Overview of the Global HIV Epidemic and Framework for Discussion of HIV Prevention Efficacy Trial Design Discussions	Glenda Gray, President and CEO, South African Medical Research Council
9:00am	Highlighting Community Priorities for HIV Prevention Trials	Jeremiah Johnson, HIV Project Director, Treatment Action Group
	Current and Future Challenges in Trial Design for Pre-Exposure Prophylaxis in HIV Prevention	Deborah Donnell, Associate Member, Fred Hutch and Principal Investigator of HPTN Statistical Data Management Center
9:15am	Issues in Microbicide Prevention Trials	Elizabeth Brown Member, Fred Hutch and Principal Investigator of MTN Statistical Data Management Center
9:30am	Ongoing Vaccine and Monoclonal Antibody Efficacy Trials in the HVTN and Considerations for Sequel Designs	Peter Gilbert, Member, Fred Hutch and Principal Investigator of HVTN Statistical Data Management Center
9:45am	The Modern Randomized Clinical Trial: Is it time to sharpen a blunt instrument?	Janet Wittes, President of Statistics Collaborative, Inc.
10:00am	Coffee/Tea Break (10:00 – 10:15am)	
Session 2 (10:15am – 12:30pm)		
10:15am	Regulatory Perspectives for Streamlining HIV Prevention Trials	Jeffrey Murray, Deputy Director of Division of Antiviral Products, Center for Drug Evaluation and Research, FDA
10:30am		
10:45am	The Averted Infections Ratio and its Connection to Other Measures of Effect	David Dunn, Professor of Medical Statistics, Medical Research Council at University College London
11:00am	Alternatives to Non-Inferiority in Trials of Novel PrEP Delivery Methods	David Glidden, Professor of Biostatistics, University of California, San Francisco
11:15am		
11:30am	Designing and Conducting Trials to Reliably Evaluate HIV Prevention Interventions	Thomas Fleming, Professor of Biostatistics, University of Washington, Seattle
11:45am		
12:00pm	Panel: Design Challenges and Approaches Developing Long-Acting, Drug-Based Prevention Products and Floor Discussion	Moderated by: Edward Cox, Director of Office of Antimicrobial Products, FDA
12:15pm		
12:30pm	Lunch Break (12:30 – 1:30pm)	
12:45pm		
1:00pm		
1:15pm		



TIME	SESSION	
1:30pm	Session 3 (1:30 – 3:40pm)	
1:45pm	Tomorrow's HIV Prevention Trials Overview of the Global HIV Epidemic and Framework	Dean Follmann, Chief of Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases
2:00pm		
2:15pm		
2:30pm	Panel: Design Challenges and Approaches for Developing Vaccines and Monoclonal Antibodies and Floor Discussion	Moderated by: Dale Hu, Chief of Vaccine Clinical Research Branch, NIAID
2:45pm		
3:00pm	Panel: Design Challenges and Approaches for Developing On-Demand Products and Floor Discussion	Moderated by: Linda-Gail Bekker, Deputy Director, Desmond Tutu HIV Centre
3:15pm		
3:30pm	Coffee/Tea Break (3:40 – 3:55pm)	
3:45pm	Session 4 (3:55 – 5:45pm)	
4:00pm	Pragmatic Trials to Bridge Efficacy to Effectiveness	Laura Balzer, Assistant Professor of Biostatistics, University of Massachusetts, Amherst
4:15pm		
4:30pm	Lessons for Future Prevention Research from TasP Cluster Randomized Trials	Victor DeGruttola, Professor of Biostatistics, Harvard University
4:45pm		
5:00pm	Panel: Priorities for future research, data collection, and funding mechanisms and Floor Discussion	Moderated by: Peggy Johnston, Independent Consultant, Vancouver BC
5:15pm		
5:30pm	Closing Remarks	Organizers
5:45pm	Symposium Closing Reception (6:30 – 8:30pm)	
6:00pm		
6:15pm		
6:30pm		
7:00pm		
7:30pm		
8:00pm		
8:30pm		

